Omega promo web banner
Omega promo Mobile banner

Novartis India Ltd - Stock Valuation and Financial Performance

BSE: 500672 | NSE: NOVARTIND | Trading | Small Cap

Novartis Share Price

1,066.35 6.00 0.57%
as on 18-Jul'25 16:59

Novartis India Ltd - Stock Valuation and Financial Performance

BSE: 500672 | NSE: NOVARTIND | Trading | Small Cap

DeciZen - make an informed investing decision on Novartis

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Novartis India stock performance -

mw4me loader
P/E Ratio (SA):
26.09
Market Cap:
2,632.9 Cr.
52-wk low:
745
52-wk high:
1,248

Is Novartis India Ltd an attractive stock to invest in?

1. Is Novartis India Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Novartis India Ltd is a average quality company.

2. Is Novartis India Ltd undervalued or overvalued?

The key valuation ratios of Novartis India Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Novartis India Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Novartis India Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

10 Year X-Ray of Novartis:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Novartis India Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 24.8%8.8%19.7%11.7%4.7%6.7%0.1%16%16.4%17.2%-
Value Creation
Index
0.8-0.40.4-0.2-0.7-0.5-1.00.10.20.2-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 690656564491438381400379335356356
Sales YoY Gr.--4.9%-14.1%-13%-10.7%-13%4.9%-5.3%-11.5%6.3%-
Adj EPS 62.120.226.213.34.67.212.641.333.740.940.9
YoY Gr.--67.5%29.8%-49.4%-65%55.2%74.6%228.9%-18.6%21.5%-
BVPS (₹) 375.6329.5299.8309.3293.4289.4281.2314.3301.8318.1317.9
Adj Net
Profit
19956.864.732.711.517.83110283.1101101
Cash Flow from Ops. 56.6-40.8161-194-23.1-69.238.744.811374.6-
Debt/CF from Ops. 0000000000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -7.1%-4.1%-3.8%6.3%
Adj EPS -4.5%54.6%48.2%21.5%
BVPS-1.8%1.6%4.2%5.4%
Share Price 1.1% 13.2% 17.6% -9.4%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
18.15.47.84.41.62.54.413.910.913.212.9
Op. Profit
Mgn %
4.63.7-1.43.23.16.86.717.519.625.725.7
Net Profit
Mgn %
28.88.711.56.72.64.77.82724.828.428.3
Debt to
Equity
00000000000
Working Cap
Days
3984296888446758911,1641,2991,3601,176380
Cash Conv.
Cycle
3026-7-20-5481-4-7305

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 12.90%

Net Profit is growing at healthy rate in last 3 years 48.21%

Sales growth has been subdued in last 3 years -3.78%

Sales growth is not so good in last 4 quarters at 6.45%

Latest Financials - Novartis India Ltd.

Standalone Consolidated
TTM EPS (₹) 40.9 -
TTM Sales (₹ Cr.) 356 -
BVPS (₹.) 317.9 -
Reserves (₹ Cr.) 773 -
P/BV 3.35 -
PE 26.09 -
From the Market
52 Week Low / High (₹) 744.95 / 1248.00
All Time Low / High (₹) 65.00 / 1436.35
Market Cap (₹ Cr.) 2,633
Equity (₹ Cr.) 12.4
Face Value (₹) 5
Industry PE 45.2

Management X-Ray of Novartis:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

No data found!

Key Ratios of Novartis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales690656564491438381400379335356
Operating Expenses 659632572479427356373314270265
Manufacturing Costs6751454441373516811
Material Costs286306246199182147178202200203
Employee Cost 157139145117114109102362319
Other Costs 149136137119906358603932
Operating Profit 3125-812122627656591
Operating Profit Margin (%) 4.5%3.7%-1.5%2.5%2.7%6.7%6.7%17.2%19.5%25.7%
Other Income 2457217478363434586242
Interest 0162685211
Depreciation 3433131210632
Exceptional Items 000000-50000
Profit Before Tax 27292158862940-4115123130
Tax 7335793419190123830
Profit After Tax 1985778521021-410385101
PAT Margin (%) 28.7%8.7%13.9%10.6%2.3%5.5%-0.9%27.3%25.4%28.3%
Adjusted EPS (₹)62.020.331.821.04.18.5-1.541.934.540.9
Dividend Payout Ratio (%)16%49%32%48%245%118%-663%113%72%61%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 1,201927740763724714694776745785
Share Capital 16141212121212121212
Reserves 1,185913727751712702682763732773
Minority Interest0000000000
Debt0000000000
Long Term Debt0000000000
Short Term Debt0000000000
Trade Payables707310691735572606251
Others Liabilities 1541,0701,2671,1634401,4301,2441,2161,0541,071
Total Liabilities 1,4252,0702,1132,0181,2372,1992,0102,0521,8611,908

Fixed Assets

Gross Block1011122485754139289
Accumulated Depreciation35799111720215
Net Fixed Assets665157664241975
CWIP 0000000000
Investments 0000000000
Inventories72885761594857554541
Trade Receivables50414446383945364140
Cash Equivalents 1,126816775612582499518556596648
Others Assets1691,1211,2331,2854831,5501,3671,3861,1721,174
Total Assets 1,4252,0702,1132,0181,2372,1992,0102,0521,8611,908

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 57-41161-194-23-69394511375
PBT 11192158862940-4115123130
Adjustment -67-56-56-73-12-5-6-49-57-39
Changes in Working Capital 92-32117-162-2-6967-249-1
Tax Paid -79-44-58-46-38-35-19238-16
Cash Flow From Investing Activity -63042469274569587-15333-3
Capex -201716-15-1430
Net Investments 00-2214187072-177-5-45
Others -6284245444392116203541
Cash Flow From Financing Activity -39-332-268-30-41-37-36-30-121-64
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid 0-100000000
Dividend Paid -32-32-28-25-25-25-25-25-117-62
Others -7-299-240-5-17-12-11-6-4-2
Net Cash Flow -61251-3850-9-1190-139267
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)18.015.389.46.891.362.91-0.5314.0711.2113.19
ROCE (%)24.778.7519.7211.74.736.670.1415.9616.3517.15
Asset Turnover Ratio0.40.380.330.290.330.260.230.20.190.21
PAT to CFO Conversion(x)0.29-0.722.06-3.73-2.3-3.29N/A0.441.330.74
Working Capital Days
Receivable Days35252328293131363938
Inventory Days46443836414339495040
Payable Days10585133181164159131119111102

Novartis India Ltd Stock News

Novartis India Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Novartis on 18-Jul-2025 16:59 is ₹1,066.4.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 18-Jul-2025 16:59 the market cap of Novartis stood at ₹2,632.9.
The latest P/E ratio of Novartis as of 18-Jul-2025 16:59 is 26.09.
The latest P/B ratio of Novartis as of 18-Jul-2025 16:59 is 3.35.
The 52-week high of Novartis is ₹1,248 and the 52-week low is ₹745.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Novartis is ₹356.3 ( Cr.) .

About Novartis India Ltd

Novartis was created in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis and its predecessor companies trace roots back more than 250 years, with a rich history of developing innovative products. From beginnings in the production of synthetic fabric dyes, the companies that eventually became Novartis branched out into producing chemicals and ultimately pharmaceuticals.

The history of Novartis traces the converging destinies of three companies: Geigy, a chemicals and dyes trading company founded in Basel, Switzerland in the middle of the 18th century; Ciba, which began producing dyes in 1859; and Sandoz, a chemical company founded in Basel in 1886.

These companies shared a common trait which lives on at Novartis: a passion for developing and marketing new products that contribute to human progress through advances in science and health. Building on this heritage, today Novartis focuses its innovation prowess on addressing the unmet needs of patients worldwide.

Since 1947, Novartis has had a significant footprint in India - committed to drug development, manufacturing, commercial and social business services. It has three legal entities namely, Novartis Healthcare Private Limited, Novartis India Limited and Sandoz Private Limited employing thousands of people. It has a rich portfolio of both innovative and established medicines addressing various therapeutic needs: cardiovascular, eye care, immunology and dermatology, metabolics, neuroscience, oncology, respiratory and organ transplant, to meet the medical needs of patients in India.

Its social business -- Arogya Parivar -- is expanding access to community education, improved infrastructure and affordable healthcare products for underserved populations in rural India.

The company’s purpose is to reimagine medicine to improve and extend people’s lives. It uses innovative science and technology to address some of society’s most challenging healthcare issues. It discover and develops breakthrough treatments and find new ways to deliver them to as many people as possible. It also aims to reward those who invest their money, time and ideas in the company.

Business area of the company

As a science-based and patient-oriented healthcare company, it strives to be a global leader in growing areas of healthcare. Following a corporate transformation Novartis globally is focused on three divisions with global scale and innovation power - pharmaceuticals, eye care and generic medicines. This has strengthened the future growth prospects of the company.

In India, the Pharmaceutical business of Novartis India Limited is focused on Bone & Pain, Calcium portfolio, Gynecology and Neurosciences and the Generics business is focused on Gynecology, Anti-TB and Anti-infectives.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...